About This Report In 2009, TNF inhibitors were the dominant drug class in terms of sales. However, there is growing use of non-TNF biologics at earlier lines of treatment, and this trend will continue over the next decade. With the first Phase III data from tasocitinib (CP-690,550; Pfizer) reaffirming efficacy with no new safety signals, novel oral small molecules could revolutionize the treatment of RA. What's Included in This ...More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Alison
+1 718 618 4897
"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...
MediPoint: Drug-Eluting Balloons - Global Analysis and Market Forecasts Summary GlobalData has released its medical devices report, “MediPoint: Drug-Eluting Balloons - Global Analysis and Market Forecasts”. ...
MediPoint: Renal Denervation - Global Analysis and Market Forecasts Summary Numerous medical device news sources and industry executives have proclaimed renal denervation to be the top medical device breakthrough ...
... To differences in known breast cancer risk factors such as reproductive hormonal factors including age at first birth or menarche and breastfeeding click to edit master subtitle style 08/11/2013 risk factors ...
... Guidelines say People with diabetes and hypertension should be treated to a systolic blood pressure goal of 140 mmhg. Lower systolic targets (such as ...
... Are also less likely to participate in cancer screening source: devaux and de looper (2012) 2009 (or nearest year) breast cancer screening in past two years cervical cancer screening in past three ...
Reportlinker.com © Copyright 2013. All rights reserved.